ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0008

CD11c+ T-Bet+ B Cells Traffic to Human Bone Marrow

Jennifer Barnas1, Diana Alzamareh2, Nida Meednu2 and Jennifer Anolik2, 1University of Rochester, Rochester, NY, 2University of Rochester Medical Center, Rochester, NY

Meeting: ACR Convergence 2022

Keywords: Aging, autoimmune diseases, B-Cell Targets, B-Lymphocyte, interferon

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: B Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: CD11c+ age/autoimmunity-associated B cells (ABC) are associated with autoantibody producing cells and disease flare in systemic lupus erythematosus. ABC were initially identified in aged mice and later shown to accumulate in autoimmune disease. The developmental origin and trafficking of ABC or their association with aging is not well understood in healthy individuals. Here, we compare human ABC frequency and phenotype in younger and older individuals with paired blood and bone marrow. We then assess responsiveness of ABC to interferon (IFN) because this is a known driver of these cells in autoimmunity.

Methods: Paired peripheral blood (PB) and bone marrow (BM) were collected from younger (Y, aged 21-27 years, n=5) and older (O, aged 52-65 years, n=5) healthy donors. Mononuclear cells were isolated by density centrifugation. Cells were treated with IFN-α2 or IFN-λ1. Cells were stained with CD3, CD14, CD11c, CD19, CD20, CD27, CD38, IgA, IgD, IgG, IgM, pSTAT1, and T-Bet antibodies for flow cytometry. Fold change of pSTAT1 median fluorescent intensity was measured after IFN treatment.

Results: CD11c+ and CD11c+ T-Bet+ B cells were found at similar frequency amongst total B cells in both blood and bone marrow in younger and older healthy donors (mean±SEM, CD11c+% of B Cells: 3.3±0.8 Y PB, 3.8±1.3 O PB, 3.3±0.9 Y BM, 2.0±0.4 O BM; CD11c+T-Bet+% of B cells 1.6±0.4 Y PB, 1.5±0.4 O PB, 1.7±0.5 Y BM, 1.2±0.1 O BM). Within the IgD- CD27- (DN) B cell compartment, there was a greater frequency of CD11c+ cells in blood (9.8±2.1% of DN) compared to the bone marrow (5.0±1.2%, Wilcoxon Matched Pairs Signed Rank Test p=0.002, n=10). CD11c+ B cells (T-Bet MFI: PB 2234±336, n=10; BM 2513±333, n=10) had higher T-Bet expression than CD11c- B cells (T-Bet MFI: PB 659±81, n=10; BM 660±79, n=10) in both blood and bone marrow. T-Bet MFI of DN B cells was higher in the blood DN B cells (4417±718, n=10) compared to those of the bone marrow (3411±524, n=10). Overall, IFN-α2 was a more potent stimulus for pSTAT1 than IFN-λ. Blood B cells responded more robustly than bone marrow B cells to type I and type III IFN stimuli. Younger bone marrow B cells responded with greater pSTAT1 fold change (3.4±0.2, n=5) to IFN-α2 than older bone marrow B cells (2.3± 0.2, n=5). CD11c- B cells (PB 6.2±0.3, BM 3.0±0.2, n=10) had greater pSTAT1 fold change than CD11c+ B cells (PB 5.4±0.3, BM 2.4±0.2, n=10) in response to IFN-α2. This was reversed for type III IFN, where CD11c+ B cells (PB 2.8±0.1, BM 1.7±0.1, n=10) responded more robustly IFN-λ1 than did CD11c- B cells (PB 2.5±0.1, BM 1.6±. 0.09).

Conclusion: Our data supports the hypothesis that ABC are generated in the periphery and circulate to the bone marrow. Although the frequency of ABC was not higher in older individuals, there were differences in their responsiveness to type I IFN.


Disclosures: J. Barnas, None; D. Alzamareh, None; N. Meednu, None; J. Anolik, None.

To cite this abstract in AMA style:

Barnas J, Alzamareh D, Meednu N, Anolik J. CD11c+ T-Bet+ B Cells Traffic to Human Bone Marrow [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/cd11c-t-bet-b-cells-traffic-to-human-bone-marrow/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cd11c-t-bet-b-cells-traffic-to-human-bone-marrow/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology